Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262004 | 0.84 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8565713 | 0.81 | EPHX2 (0.55) | EPHX2CYP2C9EPHX1TRPM8HDAC3 | |
| SCHEMBL8913667 | 0.80 | KCNH2 (0.44) | EPHX2CYP2C9HDAC3HDAC4HDAC1 | |
| SCHEMBL8913639 | 0.78 | ADRA1D (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8568665 | 0.76 | PKM (0.44) | CYP2D6 | |
| SCHEMBL12695212 | 0.75 | EPHX2 (0.78) | EPHX2CYP2C9EPHX1GPR119CYP2D6 | |
| Hydrochloric Acid SCHEMBL8565340 | 0.74 | PKM (0.43) | CYP2D6 | |
| SCHEMBL14139191 | 0.74 | GPR119 (0.74) | GPR119 | |
| SCHEMBL8566857 | 0.73 | ADRA1D (0.47) | — | |
| SCHEMBL9113519 | 0.73 | HRH3 (0.44) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | EPHX2 3139/4885CYP2C9 2505/4885EPHX1 2928/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | EPHX2 3139/4885CYP2C9 2505/4885EPHX1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.